Satoru Iwasa
Elite in Esophageal Cancer

Satoru Iwasa

Tokyo, JP 
Elite in Esophageal Cancer
Tokyo, JP 
OverviewLocationsClinical Research

Overview

Satoru Iwasa practices in Tokyo, Japan. Mr. Iwasa is rated as an Elite expert by MediFind in the treatment of Esophageal Cancer. His top areas of expertise are Stomach Cancer, Esophageal Cancer, Colorectal Cancer, Gastrectomy, and Endoscopy.

His clinical research consists of co-authoring 159 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 31 articles in the study of Esophageal Cancer.

Gender
Male

Locations

Tokyo, Japan
Other Locations
Department Of Head And Neck, 5-1-1 Tsukiji, Chuo, 1040045, Japan
Niigata, Japan
Kyoto, 1040045, Japan
St. Marianna University, 2-16-1 Sugao, Miyamae Ku, Kawasaki, 2168511, Japan
Kashiwa, 2778577, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies
An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2025
Intervention Type: Drug
Study Drug: Avelumab
Study Phase: Phase 3
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drugs: Tucatinib, Trastuzumab, Fulvestrant
Study Phase: Phase 2
Phase 1, Open-label Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-1123a in Subjects With Advanced Solid Tumors
Phase 1, Open-label Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-1123a in Subjects With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: December 24, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 2 Less Clinical Trials

159 Total Publications

ONO-4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer.
ONO-4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer.
Journal: Cancer science
Published: February 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Iwasa's expertise for a condition
ConditionClose
View All 20 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile